|
Patients with
SCIT scheduled (n=249)
|
Patients with
SCIT delayed (n=394)
|
P value
|
Age (mean±SD) |
13±11.34 |
12±11.16 |
ns |
Gender |
|
|
ns |
Male |
163 |
249 |
|
Female |
86 |
145 |
|
Treatment phase |
|
|
0.0057*
|
Build up phase1
|
54 |
53 |
|
Maintenance phase2
|
195 |
296 |
|
Diagnosis |
|
|
0.0001*
|
AR only |
246 |
363 |
|
AR +Asthma |
1 |
31 |
|
AR+Asthma+AC |
1 |
0 |
|
AR+IBS |
1 |
0 |
|
Adverse reactions(V0/V1, %) |
|
|
ns |
Immediate local reactions |
0/1.9% |
1.0%/1.9% |
|
Immediate systemic reactions |
0/1.0% |
0.3%/0.9% |
|
Delayed local reactions |
0.4%/1.0% |
1.8%/2.8% |
|
Delayed systemic reactions |
0/0 |
0/0.5% |
|
Convid-19 infection |
0 |
0 |
|